Sanmarti R, et al. - In this randomized, open-label trial, researchers estimated the effectiveness and safety of escalating the dose interval of subcutaneous tocilizumab in subjects with rheumatoid arthritis (RA) who were in clinical remission. In the single-arm phase, 179 cases achieved clinical remission and then randomized to remain with subcutaneous tocilizumab once weekly as monotherapy (TCZ-SCqw) (n=89) or switch to TCZ-SC every 2 weeks (TCZ-SCq2w) (n=90) for 24 weeks. The relationship between increasing the dosing interval of subcutaneous TCZ and a lower probability of sustaining remission after 24 weeks was reported. They did not notice a link between increasing the dosing interval of subcutaneous TCZ and better tolerability.